Lilly's retatrutide may have the best weight loss efficacy so far, but analysts are concerned around its tolerability compared with tirzepatide.
The rise in infectious disease outbreaks globally is being driven by several factors, including increased global travel and urbanisation.
Merck KGaA has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti-CEACAM5 ADC precemtabart tocentecan for mCRC.
Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating BIIB122 for early-stage Parkinson’s disease.
An upcoming conference will investigate the latest trends in the medical devices and medtech clinical trials industry with a focus on navigating recent regulatory changes. The Out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results